@ibraz4me it will interesting to see the detail on this poster...

ALA did a cap raise last week, hence they are now funded to advance their lead product ALA-101 into Phase 1 trials. They are operating in a more niche (narrow?) field, using iNKT cells to target blood cancers. Their longer term strategy is to 'arm' these CAR-inkt cells to target solid tumors. imugene are further advanced, so I wouldn't read too much into the parking of the IMU-ALA collaboration. Imugene terminated that collaboration, and whilst there may be some competitive reasons behind that, as others have posited here, it's more likely that Imugene's onCARlytics program leveraging azer-cel will take priority over external collabs given what they are seeing pre-clinically.

@ibraz4me it will interesting to see the detail on this poster presentation for RC402. And for those wanting to see what the local competition is up to with oncolytic viruses, worth taking a peek at the ImmVirx presentation for NWR Communications last week. These are mostly ex-Viralytics guys.

ImmVirX Investor Presentation - Zoom


GLTAH